Estimation of Fraction Dissolved After Intratracheal Delivery of a Potent Janus Kinase Inhibitor, iJAK-001, with Low Solubility in Rat and Sheep: Impact of Preclinical PKPD on Inhaled Human Dose Projection-Reference-Cited by-同舟云学术

Estimation of Fraction Dissolved After Intratracheal Delivery of a Potent Janus Kinase Inhibitor, iJAK-001, with Low Solubility in Rat and Sheep: Impact of Preclinical PKPD on Inhaled Human Dose Projection

Published:2019-10-01 Issue:5 Volume:32 Page:251-265
ISSN:1941-2711
Container-title:Journal of Aerosol Medicine and Pulmonary Drug Delivery
language:en
Short-container-title:Journal of Aerosol Medicine and Pulmonary Drug Delivery

Author:

Caniga Michael¹,Yu Hongshi²,Lee Hyun-Hee³,Wang Meiyao⁴,Witter David⁵,Salmon Michael⁶,Fan Peter W.⁴

Affiliation:

1. Department of In Vivo Pharmacology, Pharmacodynamics and Drug Metabolism, Merck & Co., Inc.Boston, Massachusetts.

2. Department of Discovery Pharmaceutical Sciences, Pharmacodynamics and Drug Metabolism, Merck & Co., Inc.Boston, Massachusetts.

3. Department of Discovery Immunology, Pharmacodynamics and Drug Metabolism, Merck & Co., Inc.Boston, Massachusetts.

4. Department of Pharmacokinetics, Pharmacodynamics and Drug Metabolism, Merck & Co., Inc.Boston, Massachusetts.

5. Preclinical Research, Cullinan Oncology, Cambridge, Massachusetts.

6. Platform Translation and Development, Emulate, Inc., Boston, Massachusetts.

Publisher

Mary Ann Liebert Inc

Subject

Pharmacology (medical),Pharmaceutical Science,Pulmonary and Respiratory Medicine

Link

https://www.liebertpub.com/doi/pdf/10.1089/jamp.2018.1492

Reference41 articles.

1. Potential for long-acting muscarinic antagonists in chronic obstructive pulmonary disease

2. Inhaled corticosteroid and long-acting β2-agonist pharmacological profiles: effective asthma therapy in practice

3. Preclinical to Clinical Translation of Tofacitinib, a Janus Kinase Inhibitor, in Rheumatoid Arthritis

4. JAK–STAT Signaling as a Target for Inflammatory and Autoimmune Diseases: Current and Future Prospects

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. JAK3 inhibitor suppresses multipotent ILC2s and attenuates steroid-resistant asthma;Science Advances;2023-12-22

2. Inhibition of multipotent ILC2s by JAK3 inhibitor attenuates steroid-resistant asthma;2023-02-28

3. JAK inhibitors for asthma;Journal of Allergy and Clinical Immunology;2021-10

4. NHC-catalyzed β-specific addition of N-based nucleophiles to allenoates;Organic Chemistry Frontiers;2020

5. Inhaled Janus Kinase (JAK) inhibitors for the treatment of asthma;Bioorganic & Medicinal Chemistry Letters;2019-10